Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis

Hepatology

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Liver Transpl

Younossi ZM

doi: 10.1002/lt.25003.

Hepatology

Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib

J Hepatol.

Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Diehl AM, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Djedjos CS, Xu R, Han L, Subramanian GM, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R

doi: 10.1016/j.jhep.2018.09.024.

Hepatology

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

Hepatology.

Harrison SA, Rossi SJ, Paredes AH, Trotter JF, Bashir MR, Guy CD, Banerjee R, Jaros MJ, Owers S, Baxter BA, Ling L, DePaoli AM

doi: 10.1002/hep.30590.

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease

Gastroenterology.

Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, Chung C, Ray AS, Subramanian GM, Myers RP, Middleton MS, Lai M, Charlton M, Harrison SA

doi: 10.1053/j.gastro.2018.07.027.

Hepatology

Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Am J Gastroenterol

Castellana M, Donghia R, Guerra V, Procino F, Castellana F, Zupo R, Lampignano L, Sardone R, De Pergola G, Romanelli F, Trimboli P, Giannelli G

doi: 10.14309/ajg.0000000000001337

Hepatology

Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis

doi: 10.1002/hep.30368.

HepatitisHepatology

Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease

Am J Gastroenterol.

Chan TT, Chan WK, Wong GL, Chan AW, Nik Mustapha NR, Chan SL, Chong CC, Mahadeva S, Shu SS, Lai PB, Chan HL, Wong VW

doi: 10.14309/ajg.0000000000000588.

HepatitisHepatology

Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B

Hepatology.

Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K

doi: 10.1002/hep.30857.

Hepatology

Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments

Z Gastroenterol.

Roeb E, Geier A

doi: 10.1055/a-

Related content

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease

Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis

Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease

Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B

Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments